Reviewing the Latest Bladder Cancer Practice Guidelines
Elizabeth R. Plimack, MD, MS, FASCO
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Diagnosis and Management of Metastatic PDAC
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Chemotherapy Strategies for Metastatic PDAC
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
Management of HR+, HER2- High-Risk EBC
Expert Viewpoint: Optimizing Breast Cancer Treatment
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
The Evolving Treatment Landscape for MBC: Emerging Therapies
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Aparna R. Parikh, MD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.